Drugmakers face mounting pressure to reveal internal rates of return on their research and development investment, given concerns from disgruntled shareholders that cash is being frittered away. That’s the view of Chris Stirling, European head of chemicals and pharmaceuticals at KPMG, whose organisation will publish a new report on Thursday revealing that industry returns on research spending nearly halved between 1990 and 2010.
